Alexion Pharmaceuticals (ALXN +4.2%) moves up on talk that Roche (RHHBY.PK +1.2%) is considering...

Alexion Pharmaceuticals (ALXN +4.2%) moves up on talk that Roche (RHHBY.PK +1.2%) is considering a bid as high as $128 for the company. That might be an expensive price tag for a "one trick pony," however, considering company has only one commercially approved drug, Solaris, whose distincion is that it's considered the most expensive drug on the market - with an average cost of over $400k per patient.

From other sites
Comments (1)
  • akoshi
    , contributor
    Comments (88) | Send Message
    I have a feeling ALXN will soon have two drugs on the market. Plus they recently raised their outlook on greater Soliris sales for the year.
    Looks to me like a solid company.
    4 Aug 2012, 04:00 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs